Novel Bivalent and D-Peptide Ligands of CXCR4 Mobilize Hematopoietic Progenitor Cells to the Blood in C3H/HeJ Mice

Overview

Journal Cell Transplant

Specialties Cell Biology
General Surgery

Date 2018 Jul 12

PMID 29991278

Citations 4

Authors

Yujia Mao

Qian Meng

Panpan Song

Siyu Zhu

Yan Xu

Evan Y Snyder

Jing An

Ziwei Huang

Affiliations

Soon will be listed here.

Abstract

The interaction of SDF-1α (also known as CXCL12) with the CXCR4 receptor plays a critical role in the retention of hematopoietic stem cells (HSCs) in bone marrow. The viral macrophage inflammatory protein-II (vMIP-II), a human herpesvirus-8 (HHV-8)-encoded viral chemokine, can bind the CXCR4 receptor and inhibit endogenous ligand-induced calcium responses and cell migration. Previously, we used the bivalent ligand approach to link synthetically two unnatural D-amino acid peptides derived from the N-terminus of vMIP-II (DV1 and DV3, respectively) to generate a dimeric peptide, DV1-K-(DV3) (also named HC4319), which shows very high affinity for CXCR4. Here, we studied the biological effects of this dimeric peptide, HC4319, and its monomeric counterpart, DV1, on SDF-1α-induced signaling in CXCR4- or CXCR7-transfected Chinese hamster ovary cells and mobilization of hematopoietic progenitor cells (HPCs) in C3H/HeJ mice using an HPC assay. HC4319 and DV1 inhibited significantly the phosphorylation of Akt and Erk, known to be downstream signaling events of CXCR4. This in vivo study in C3H/HeJ mice showed that HC4319 and DV-1 strongly induced rapid mobilization of granulocyte-macrophage colony-forming units (CFUs), erythrocyte burst-forming units, and granulocyte-erythrocyte-monocyte-megakaryocyte CFUs from the bone marrow to the blood. These results provide the first reported experimental evidence that bivalent and D-amino acid peptides derived from the N-terminus of vMIP-II are potent mobilizers of HPCs in C3H/HeJ mice and support the further development of such agents for clinical application.

Citing Articles

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs.

Meng Q, Zhu R, Mao Y, Zhu S, Wu Y, Huang L Biosci Rep. 2023; 43(12).

PMID: 38131305 PMC: 10987480. DOI: 10.1042/BSR20230981.

Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer.

Wang T, Wang D, Sun Y, Zhuang T, Li X, Yang H J Exp Clin Cancer Res. 2023; 42(1):297.

PMID: 37950281 PMC: 10636825. DOI: 10.1186/s13046-023-02870-3.

Co-receptor signaling in the pathogenesis of neuroHIV.

Nickoloff-Bybel E, Festa L, Meucci O, Gaskill P Retrovirology. 2021; 18(1):24.

PMID: 34429135 PMC: 8385912. DOI: 10.1186/s12977-021-00569-x.

High affinity CXCR4 inhibitors generated by linking low affinity peptides.

Zhang C, Huang L, Zhu R, Meng Q, Zhu S, Xu Y Eur J Med Chem. 2019; 172:174-185.

PMID: 30978562 PMC: 6677133. DOI: 10.1016/j.ejmech.2019.03.056.

References

Zhou N, Luo Z, Luo J, Hall J, Huang Z . A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. Biochemistry. 2000; 39(13):3782-7. DOI: 10.1021/bi992750v. View

Szpakowska M, Chevigne A . vCCL2/vMIP-II, the viral master KEYmokine. J Leukoc Biol. 2015; 99(6):893-900. DOI: 10.1189/jlb.2MR0815-383R. View

Takami S, Minami M, Nagata I, Namura S, Satoh M . Chemokine receptor antagonist peptide, viral MIP-II, protects the brain against focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2001; 21(12):1430-5. DOI: 10.1097/00004647-200112000-00007. View

Rubant S, Ludwig R, Pfeffer J, Schulze-Johann P, Kaufmann R, Pfeilschifter J . Eukaryotic expression of the broad-spectrum chemokine receptor antagonist vMIP-II and its effects on T-cell function in vitro and in vivo. Exp Dermatol. 2006; 15(8):634-42. DOI: 10.1111/j.1600-0625.2006.00455.x. View

Ghirnikar R, Lee Y, Eng L . Chemokine antagonist infusion attenuates cellular infiltration following spinal cord contusion injury in rat. J Neurosci Res. 2000; 59(1):63-73. View

LiWang A, Cao J, Zheng H, Lu Z, Peiper S, LiWang P . Dynamics study on the anti-human immunodeficiency virus chemokine viral macrophage-inflammatory protein-II (VMIP-II) reveals a fully monomeric protein. Biochemistry. 1999; 38(1):442-53. DOI: 10.1021/bi9812726. View

Lapidot T, Kollet O . The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia. 2002; 16(10):1992-2003. DOI: 10.1038/sj.leu.2402684. View

Yang Q, Zhang F, Ding Y, Huang J, Chen S, Wu Q . Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer. Br J Cancer. 2014; 110(5):1288-97. PMC: 3950870. DOI: 10.1038/bjc.2014.1. View

Balabanian K, Lagane B, Infantino S, Chow K, Harriague J, Moepps B . The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem. 2005; 280(42):35760-6. DOI: 10.1074/jbc.M508234200. View

10.

Aiuti A, Webb I, Bleul C, Springer T, Gutierrez-Ramos J . The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997; 185(1):111-20. PMC: 2196104. DOI: 10.1084/jem.185.1.111. View

11.

Pillai R, Beutelspacher S, Larkin D, George A . Expression of the chemokine antagonist vMIP II using a non-viral vector can prolong corneal allograft survival. Transplantation. 2008; 85(11):1640-7. DOI: 10.1097/TP.0b013e318172813f. View

12.

Bleul C, Fuhlbrigge R, Casasnovas J, Aiuti A, Springer T . A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996; 184(3):1101-9. PMC: 2192798. DOI: 10.1084/jem.184.3.1101. View

13.

Burns J, Summers B, Wang Y, Melikian A, Berahovich R, Miao Z . A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006; 203(9):2201-13. PMC: 2118398. DOI: 10.1084/jem.20052144. View

14.

Choi W, Duggineni S, Xu Y, Huang Z, An J . Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J Med Chem. 2011; 55(3):977-94. PMC: 3476736. DOI: 10.1021/jm200568c. View

15.

Xu Y, Duggineni S, Espitia S, Richman D, An J, Huang Z . A synthetic bivalent ligand of CXCR4 inhibits HIV infection. Biochem Biophys Res Commun. 2013; 435(4):646-50. PMC: 3752463. DOI: 10.1016/j.bbrc.2013.05.038. View

16.

Qin L, Kufareva I, Holden L, Wang C, Zheng Y, Zhao C . Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science. 2015; 347(6226):1117-22. PMC: 4362693. DOI: 10.1126/science.1261064. View

17.

Weber K, Grone H, Rocken M, Klier C, Gu S, Wank R . Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur J Immunol. 2001; 31(8):2458-66. DOI: 10.1002/1521-4141(200108)31:8<2458::aid-immu2458>3.0.co;2-l. View

18.

Ganju R, Brubaker S, Meyer J, Dutt P, Yang Y, Qin S . The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem. 1998; 273(36):23169-75. DOI: 10.1074/jbc.273.36.23169. View

19.

Luo Z, Fan X, Zhou N, Hiraoka M, Luo J, Kaji H . Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II. Biochemistry. 2000; 39(44):13545-50. DOI: 10.1021/bi000633q. View

20.

Sozzani S, Luini W, Bianchi G, Allavena P, Wells T, Napolitano M . The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood. 1998; 92(11):4036-9. View